Biogen Inc. (Nasdaq: BIIB) announced today that Michael McDonnell, Executive Vice President and Chief Financial Officer, will retire from his role on February 28, 2025. Upon his retirement, Robin Kramer, currently Biogen’s Chief Accounting Officer, will step into the Chief…
Lupin Limited, a global leader in pharmaceuticals, has announced a strategic shift toward developing respiratory inhalers with propellants that have near-zero global warming potential (GWP). This initiative aims to provide patients with pressurized metered dose inhalers (pMDIs) that maintain the…
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on transforming care for patients with autoimmune and inflammatory diseases, has announced the presentation of new translational data on its receptor-interacting protein kinase 2 (RIPK2) scaffolding inhibitor, OD-07656, at the American College…
Judo Bio, a biotechnology company focused on developing oligonucleotide medicines for kidney delivery, has announced the presentation of preclinical data demonstrating a mechanism for the uptake and trafficking of ligand-siRNA conjugates via megalin receptors. This mechanism enables targeted gene knockdown…
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, has announced an agreement to sell 6,758,311 of its common shares at a price of $8.90 per share. This financing round is expected to close on October 29, 2024, pending…
Maze Therapeutics, a clinical-stage biopharmaceutical company focused on leveraging human genetics to create innovative small molecule precision medicines for common diseases, has announced promising results from the Phase 1 clinical trial of its drug candidate MZE829 in healthy volunteers. MZE829…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced updates on its kidney disease pipeline, which includes treatments for IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and APOL1-mediated kidney disease (AMKD). These updates highlight the transformative potential of Vertex’s investigational therapies and include…
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company specializing in targeted therapies for RAS-driven cancers, has announced promising early data on RMC-9805, a selective inhibitor for the RAS(ON) G12D mutation. The preliminary safety and antitumor results for RMC-9805 were…
D.A. Davidson has announced its role as the exclusive sell-side financial advisor to Allivet, Inc., an online pet pharmacy specializing in medications, supplements, and various pet products, regarding its upcoming sale to Tractor Supply Company (NASDAQ: TSCO). Founded in 1992…
GenSight Biologics Reports €3.4 Million Cash Position as of September 30, 2024, and Business Update GenSight Biologics (“GenSight” or the “Company”) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company dedicated to developing innovative gene therapies for retinal neurodegenerative diseases…
Launch of Access to Health Initiative Announced at World Stroke Congress The World Stroke Organization (WSO) President, Dr. Sheila Martins, officially launched the Access to Health initiative at the annual World Stroke Congress in Abu Dhabi. This collaboration with Merz…
eyonis™ LCS Achieves Key Milestones in REALITY Study; Upcoming Webcast Scheduled Key Highlights: Operational and Financial Overview:Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announced that its Board of Directors approved the consolidated IFRS financial statements for H1 2024 on October 23,…
